We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA: Access Policy to Balance Transparency, Confidentiality
EMA: Access Policy to Balance Transparency, Confidentiality
December 8, 2010
As the European Medicines Agency (EMA) implements its new public access policy, which includes the release of clinical trial data for drugs that have been approved, it is promising to balance transparency with the need to protect confidential company information.